Search

Displaying results 4031 - 4040 of 8196 in total
  1. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

  2. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]

  3. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  4. Drug

    Autologous DNP-conjugated tumour vaccine

    go.drugbank.com/drugs/DB17361
    Investigational

    Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]

  5. Drug

    Trotabresib

    go.drugbank.com/drugs/DB17421
    Investigational

    Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

  6. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  7. Drug

    Sparsomycin

    go.drugbank.com/drugs/DB04222
    Experimental

    An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

  8. Drug

    AMT-080

    go.drugbank.com/drugs/DB17846
    Experimental

    AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.

  9. Drug

    CTX130

    go.drugbank.com/drugs/DB18627
    Investigational

    CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

  10. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.